MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Type of Assessment:

Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.

BMC Cancer 2018 November 29 [Link] Schwartz RM, Lieberman-Cribbin W, Wolf A, Flores RM, Taioli E Abstract BACKGROUND: Few studies have focused on quality of life (QoL) after treatment of malignant pleural mesothelioma (MPM). There are still questions as to which surgical procedure, extrapleural pneumonectomy (EPP) or pleurectomy decortication (P/D) is most effective and results […]

Comments Off on Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.

The significance of non-occupational asbestos exposure in women with mesothelioma.

Respirology Case Reports 2018 November 20 [Link] Tlotleng N, Sidwell Wilson K, Naicker N, Koegelenberg CF, Rees D, Phillips JI Abstract Malignant mesothelioma is a rare and aggressive pleural or peritoneal tumour almost always caused by exposure to asbestos fibres. Exposure to asbestos can cause malignant mesothelioma 30-40 years after exposure. A description of sources of […]

Comments Off on The significance of non-occupational asbestos exposure in women with mesothelioma.

Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.

European Journal of Surgical Oncology 2018 October 19 [Link] Deraco M, Nizri E, Glehen O, Baratti D, Tuech JJ, Bereder JM, Kepenekian V, Kusamura S, Goere D Abstract BACKGROUND: Well differentiated papillary peritoneal mesothelioma (WDPPM) is a rare variant of mesothelioma which affects mainly women in the reproductive age. The disease may present multifocally and […]

Comments Off on Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.

Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

The Journal of Thoracic and Cardiovascular Surgery 2018 October 22 [] Verma V, Ahern CA, Berlind CG, Lindsay WD, Grover S, Friedberg JS, Simone CB Abstract OBJECTIVES: There are 2 main treatment paradigms recognized by the National Comprehensive Cancer Network for resectable malignant pleural mesothelioma (MPM): induction chemotherapy followed by resection (IC/R), and up-front resection […]

Comments Off on Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?

Translational Lung Cancer Research 2018 October [Link] Halford P, Clive AO Malignant pleural mesothelioma has a high morbidity and poor prognosis. Most patients undergo invasive pleural interventions to either facilitate diagnosis and/or alleviate symptoms from malignant pleural effusion. Procedure tract metastasis (PTM) are a well-known complication of pleural procedures in mesothelioma and there has been […]

Comments Off on Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?

A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).

Translational Lung Cancer Research 2018 October [Link] Raskin J, Surmont V, Cornelissen R, Baas P, van Schil PEY, van Meerbeeck JP Abstract Radical multimodality treatment for malignant pleural mesothelioma (MPM) is controversial, with intense debate (but lack of data) about which surgical procedure to perform [extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD)], if any. In order […]

Comments Off on A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).

Update on the management of malignant peritoneal mesothelioma.

Translational Lung Cancer Research 2018 October [Link] Sugarbaker PH Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease whose natural history is confined to the peritoneal space. Systemic chemotherapy has little impact on survival of patients with MPM. A surgical procedure with a goal of resection of all visible evidence of disease, called cytoreductive surgery […]

Comments Off on Update on the management of malignant peritoneal mesothelioma.

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

Lung Cancer 2018 November [Link] Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Sato A, Tsujimura T, Ueda H, Makihata S, Kato F, Iwasaki A, Nabeshima K Abstract OBJECTIVES: Histologic diagnosis of malignant pleural mesothelioma (MPM) is not always straightforward. Loss of BRCA1-associated protein 1 (BAP1) expression as detected by immunohistochemistry (IHC) (BAP1 IHC) and […]

Comments Off on A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Lung Cancer 2018 November [Link] Rosskamp M, Macq G, Nackaerts K, Praet M, Van Eycken L, Van Meerbeeck JP, De Schutter H Abstract OBJECTIVES: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, for which treatment is often limited to palliative combination chemotherapy. Multimodality-therapy, including radical surgery, is largely restricted to clinical trials, leaving […]

Comments Off on Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.

International Journal of Molecular Science 2018 November 10 [Link] Mungo E, Bergandi L, Salaroglio IC, Doublier S Abstract Emerging evidence supports the idea that a dysfunction in cell metabolism could sustain a resistant phenotype in cancer cells. As the success of chemotherapeutic agents is often questioned by the occurrence of multidrug resistance (MDR), a multiple […]

Comments Off on Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.